

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

GENEOSCOPY, INC.,  
Petitioner,

v.

EXACT SCIENCES CORPORATION,  
Patent Owner.

---

Case No.: IPR2024-01330  
U.S. Patent 11,970,746

---

**DECLARATION OF DUNCAN WHITNEY, Ph.D.**

TABLE OF CONTENTS

I. Introduction..... 1

II. Qualifications and Experience..... 2

III. The Person of Ordinary Skill in the Art ..... 5

IV. Technical Background..... 7

    A. Diagnostic Analysis of Biological Samples..... 8

        1. Diagnostic Tests Based on Detection of Biomarkers, such as Protein and DNA ..... 10

        2. Sensitivity and Specificity as Measures of Diagnostic Performance ..... 13

        3. Diagnostic Tests Commonly Measure Multiple Markers 14

        4. Diagnostic Analyses Require Well-Preserved Samples 16

    B. Use of Fecal Diagnostic Tests to Diagnose Colorectal Cancer 24

        1. Fecal Occult Blood Tests ..... 24

        2. Fecal DNA-Based Tests..... 28

        3. RNA Expression was also used to Diagnose Colorectal Cancer ..... 33

    C. Biomarker Panels Empower Broader and Earlier Detection of Colorectal Cancer ..... 34

        1. Panels of Different Fecal DNA biomarkers..... 34

        2. Panels Combining DNA Biomarkers and FOBT..... 35

    D. Home Collection of Fecal Samples ..... 39

        1. Collecting and Partitioning Stool Samples ..... 40

        2. Different Buffers were Used to Preserve Different Biomarkers in Fecal Samples..... 49

DECLARATION OF DUNCAN WHITNEY

3. Partitioning Samples into Multiple Vessels for Stabilization during Shipment..... 54

V. Legal Standards ..... 57

VI. The Challenged Patent..... 61

    A. The '746 Patent ..... 61

    B. Summary of the Claimed Subject Matter..... 65

VII. SUMMARY OF SELECTED PRIOR ART REFERENCES ..... 71

    A. Lenhard (EX1004)..... 71

    B. Vilkin (EX1005)..... 77

    C. Itzkowitz (EX1006)..... 82

    D. Kanaoka (EX1007)..... 86

    E. Shuber (EX1008)..... 89

    F. Inbar (EX1009)..... 92

VIII. OVERVIEW OF GROUNDS OF UNPATENTABILITY ..... 97

IX. THE CLAIMS OF THE '746 PATENT ARE ANTICIPATED AND/OR OBVIOUS..... 98

    A. Lenhard in view of Itzkowitz and Vilkin renders claims 1-4 and 14-19 obvious ..... 98

        1. A POSA would be motivated to use the iFOBT of Vilkin in place of the gFOBT of Lenhard..... 100

        2. A POSA would have been motivated to use the sample collection methodology of Itzkowitz in Lenhard's process ..... 104

        3. A POSA would have been motivated to use the DNA stabilizing buffer of Itzkowitz in Lenhard's process ... 106

        4. Claim 1 ..... 110

..

DECLARATION OF DUNCAN WHITNEY

5. Claim 2: “The method of claim 1, further comprising delivering the sealable vessel containing the first portion of the fecal sample and the stabilizing buffer and the sealable container containing the second portion of the fecal sample and the solution to a medical diagnostics laboratory”. 122

6. Claim 3 ..... 123

7. Claim 4: “The method of claim 3, wherein testing the nucleic acid comprises determining expression from a human gene.” ..... 129

8. Claim 14: “The method of claim 3, wherein testing for an amount of a blood protein present in the second portion comprises testing for a concentration of hemoglobin in the second portion, wherein a concentration of hemoglobin is indicative of a presence of blood in the fecal sample.” 131

9. Claim 15: “The method of claim 14, wherein the testing for the concentration of hemoglobin comprises immunochemical detection of hemoglobin.” ..... 132

10. Claims 16-19: “The method of claim 14, wherein the second portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the second portion is at least [5, 10, 20, or 50] ng/ml.” ..... 132

B. Lenhard in view of Itzkowitz and Vilkin, in further view of Kanaoka renders obvious claims 12 and 13 ..... 135

1. Claim 12: “The method of claim 4, wherein determining expression from the human gene comprises measuring an amount of RNA expressed from the human gene.” ..... 135

2. Claim 13: “The method of claim 12, wherein measuring an amount of RNA expressed from the human gene comprises reverse transcriptase polymerase chain reaction (RT-PCR)” ..... 138

C. Shuber and Vilkin render obvious claims 1-4, and 14-19..... 139

1. Claim 1 ..... 144

...

DECLARATION OF DUNCAN WHITNEY

- 2. Claim 2: “The method of claim 1, further comprising delivering the sealable vessel containing the first portion of the fecal sample and the stabilizing buffer and the sealable container containing the second portion of the fecal sample and the solution to a medical diagnostics laboratory”. 151
- 3. Claim 3 ..... 152
- 4. Claim 4: “The method of claim 3, wherein testing the nucleic acid comprises determining expression from a human gene.” ..... 155
- 5. Claim 14: “The method of claim 3, wherein testing for an amount of a blood protein present in the second portion comprises testing for a concentration of hemoglobin in the second portion, wherein a concentration of hemoglobin is indicative of a presence of blood in the fecal sample.” 156
- 6. Claim 15: “The method of claim 14, wherein the testing for the concentration of hemoglobin comprises immunochemical detection of hemoglobin.” ..... 157
- 7. Claims 16-19: “The method of claim 14, wherein the second portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the second portion is at least [5, 10, 20, or 50] ng/ml.” ..... 157
- D. Shuber and Vilkin, in view of Kanaoka render obvious claims 12 and 13 ..... 160
  - 1. Claim 12 “The method of claim 4, wherein determining expression from the human gene comprises measuring an amount of RNA expressed from the human gene.” ..... 160
  - 2. Claim 13: “The method of claim 12, wherein measuring an amount of RNA expressed from the human gene comprises reverse transcriptase polymerase chain reaction (RT-PCR) ..... 163
- E. Inbar anticipates claims 1 and 2 ..... 163
  - 1. Claim 1 ..... 171

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.